| COVID-19 |
1 |
1 |
| Heart Failure (HF) |
0 |
0.9 |
| Hypertension |
0 |
0.8 |
| Heart |
0 |
0.75 |
| Cardiovascular Risk Management |
0 |
0.74 |
| Myocardial Infarction (MI) |
0 |
0.51 |
| Diuretics |
0 |
0.38 |
| Blood |
0 |
0.25 |
| Pandemic |
0 |
0.25 |
| Acute Myocardial Infarction (MI) |
0 |
0.21 |
| Lipids Management |
0 |
0.21 |
| ST Segment Elevation Myocardial Infarction |
0 |
0.18 |
| Biomarker |
0 |
0.13 |
| Clinical Guidelines |
0 |
0.99 |
| Dyslipidemia |
0 |
0.13 |
| Fish Oil |
0 |
0.13 |
| Gene Editing |
0 |
0.13 |
| Herbal Medicine |
0 |
0.13 |
| Infarction |
0 |
0.13 |
| Medical Conferences |
0 |
0.13 |
| Peer Review |
0 |
0.13 |
| Complementary and Alternative Medicine |
0 |
0.11 |
| Genomic Medicine |
0 |
0.11 |
| Neuroendocrine Tumor |
0 |
0.11 |
| Social Determinants of Health |
0 |
0.11 |